Pentoxifylline (Standard)

Pentoxifylline (Standard) is the analytical standard of Pentoxifylline. This product is intended for research and analytical applications. Pentoxifylline (BL-191), a haemorheological agent, is an orally active non-selective phosphodiesterase (PDE) inhibitor, with immune modulation, anti-inflammatory, hemorheological, anti-fibrinolytic and anti-proliferation effects. Pentoxifylline can be used for the research of peripheral vascular disease, cerebrovascular disease and a number of other conditions involving a defective regional microcirculation[1][2][3].

Product Specifications

CAS Number

[6493-05-6]

Product Name Alternative

BL-191 (Standard) ; PTX (Standard) ; Oxpentifylline (Standard)

UNSPSC

12352005

Hazard Statement

H302-H312-H332-H336

Target

Autophagy; HIV; Phosphodiesterase (PDE) ; Reference Standards

Type

Reference compound

Related Pathways

Anti-infection; Autophagy; Metabolic Enzyme/Protease; Others

Field of Research

Cardiovascular Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/pentoxifylline-standard.html

Solubility

10 mM in DMSO

Smiles

O=C(N1CCCCC(C)=O)N(C)C2=C(N(C)C=N2)C1=O

Molecular Formula

C13H18N4O3

Molecular Weight

278.31

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Iffat Hassan, et al. Pentoxifylline and its applications in dermatology. Indian Dermatol Online J. 2014 Oct-Dec; 5 (4) : 510–516.|[2]A Ward, et al. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs. 1987 Jul;34 (1) :50-97.|[3]Yessica Cristina Castellanos-Esparza, et al. Synergistic promoting effects of pentoxifylline and simvastatin on the apoptosis of triple-negative MDA-MB-231 breast cancer cells. Int J Oncol. 2018 Apr;52 (4) :1246-1254.|[4]Shabnam Movassaghi, et al. Effect of Pentoxifylline on Ischemia- induced Brain Damage and Spatial Memory Impairment in Rat. Iran J Basic Med Sci. 2012 Sep-Oct; 15 (5) : 1083-1090.